TREACE MEDICAL CONCEPTS INC
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
TMCI$4.03-3.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $12,110 | $12,982 |
| Marketable securities, short-term | 70,689 | 110,216 |
| Accounts receivable, net of allowance for credit losses of $743 and $980 as of September 30, 2024 and December 31, 2023, respectively | 24,177 | 38,063 |
| Inventories | 43,611 | 29,245 |
| Prepaid expenses and other current assets | 7,015 | 7,853 |
| Total current assets | 157,602 | 198,359 |
| Property and equipment, net | 25,168 | 22,298 |
| Intangible assets, net of accumulated amortization of $1,188 and $475 as of September 30, 2024 and December 31, 2023, respectively | 8,312 | 9,025 |
| Goodwill | 12,815 | 12,815 |
| Operating lease right-of-use assets | 8,569 | 9,264 |
| Other non-current assets | 458 | 146 |
| Total assets | $212,924 | $251,907 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $18,649 | $11,835 |
| Accrued liabilities | 8,098 | 10,458 |
| Accrued commissions | 5,347 | 10,759 |
| Accrued compensation | 5,598 | 7,549 |
| Other liabilities | 571 | 4,432 |
| Total current liabilities | 38,263 | 45,033 |
| Long-term debt, net of discount of $769 and $992 as of September 30, 2024 and December 31, 2023, respectively | 53,231 | 53,008 |
| Operating lease liabilities, net of current portion | 16,487 | 15,891 |
| Other long-term liabilities | 37 | 37 |
| Total liabilities | 108,018 | 113,969 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value, 300,000,000 shares authorized; 62,294,975 and 61,749,654 issued, and 62,275,371 and 61,749,654 outstanding as of September 30, 2024 and December 31, 2023, respectively | 62 | 62 |
| Additional paid-in capital | 294,392 | 271,973 |
| Accumulated deficit | (189,489) | (134,247) |
| Accumulated other comprehensive (loss) income | 191 | 163 |
| Treasury stock, at cost; 19,604 and 1,218 shares as of September 30, 2024 and December 31, 2023, respectively | (250) | (13) |
| Total stockholders’ equity | 104,906 | 137,938 |
| Total liabilities and stockholders’ equity | $212,924 | $251,907 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.